Chardan Rates Regeneron A Sell, Advises Caution By: Benzinga via Benzinga September 30, 2016 at 14:37 PM EDT Regeneron Pharmaceuticals Inc (NASDAQ: REGN) top line results from a mid-stage study of Eylea co-formulated with rinuccumab ... Read More >> Related Stocks: Alnylam Pharmaceuticals Amgen Medicines Company Ophthotech Corp Regeneron Pharmaceuticals Sanofi-Aventis S.A. ADR